```
JOHN D. CLINE (CA State Bar No. 237759)
   50 California Street, Suite 1500
   San Francisco, CA 94111
   Telephone: (415) 662-2260 | Facsimile: (415) 662-2263
   Email: cline@johndclinelaw.com
 3
  KEVIN M. DOWNEY (Admitted Pro Hac Vice)
   LANCE A. WADE (Admitted Pro Hac Vice)
   AMY MASON SAHARIA (Admitted Pro Hac Vice)
   KATHERINE TREFZ (CA State Bar No. 262770)
   WILLIAMS & CONNOLLY LLP
6
   725 Twelfth Street, NW
   Washington, DC 20005
    Telephone: (202) 434-5000 | Facsimile: (202) 434-5029
   Email: KDowney@wc.com; LWade@wc.com; ASaharia@wc.com; KTrefz@wc.com
9
   Attorneys for Defendant ELIZABETH A. HOLMES
10
11
                              UNITED STATES DISTRICT COURT
12
                            NORTHERN DISTRICT OF CALIFORNIA
13
                                     SAN JOSE DIVISION
14
    UNITED STATES OF AMERICA.
                                             Case No. CR-18-00258-EJD
15
                                             MS. HOLMES' REPLY IN SUPPORT OF
         Plaintiff,
16
                                             MOTION TO EXCLUDE EXPERT
                                              TESTIMONY OR, IN THE ALTERNATIVE,
17
                                              COMPEL ADEQUATE RULE 16 DISCLOSURE
   ELIZABETH HOLMES and
18
   RAMESH "SUNNY" BALWANI,
                                                     July 20, 2020
                                             Date:
                                             Time:
                                                     10:00 a.m.
19
         Defendants.
                                              CTRM: 4, 5th Floor
20
                                             Hon. Edward J. Davila
21
22
23
24
25
26
   MS. HOLMES' REPLY IN SUPPORT OF MOTION TO EXCLUDE EXPERT TESTIMONY
27
   OR, IN THE ALTERNATIVE, COMPEL ADEQUATE RULE 16 DISCLOSURE
   CR-18-00258 EJD
28
```

## TABLE OF CONTENTS

2			
3	INTRODUCTION		
	ARGUMENT.		2
4	I.	The Rule 16 Standards Apply to These Witnesses.	
5		A. Rule 16 Applies to All Expert Testimony	
6		B. The Government Must Provide More Than "Generic" Descriptions	
7		The Government's Disclosure Remains Inadequate	
8		A. The Government Failed To Provide a Summary for Its Experts' Opinions and the Bases and Reasons for Those Opinions	9
9		B. The Government's Discovery Does Not Cure Its Insufficient Disclosure	9
10	CONCLUSION		
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27		EPLY IN SUPPORT OF MOTION TO EXCLUDE EXPERT TESTIMONY TERNATIVE, COMPEL ADEQUATE RULE 16 DISCLOSURE	

28 | CR-18-00258 EJD

## **TABLE OF AUTHORITIES CASES** Fresenius Med. Care Holdings v. Baxter Int'l, Inc., 2006 WL 1330002 (N.D. Cal. May 15, 2006)....... 4 **RULES** Fed. R. Evid. 702 passim MS. HOLMES' REPLY IN SUPPORT OF MOTION TO EXCLUDE EXPERT TESTIMONY OR, IN THE ALTERNATIVE, COMPEL ADEQUATE RULE 16 DISCLOSURE CR-18-00258 EJD

# 

#### **INTRODUCTION**

Rather than engage with Ms. Holmes' arguments about the infirmities of its Rule 16 disclosure, the government argues for a lesser standard for its "fact" expert witnesses. Gov't Opp'n to Mot. To Exclude Expert Testimony ("Gov't Opp'n), ECF No.441, at 8-10. According to the government, because the at-issue witnesses are percipient witnesses and "are not primarily expert witnesses," its paltry Rule 16 disclosures are sufficient. The Court must reject this argument.

As an initial matter, the government's disclosure makes clear that these witnesses will be proffering expert opinions that go to a core issue in this case: the government's allegation, underlying the alleged patient conspiracy, that Theranos tests were "inaccurate." *Id.* at 1. These are not merely percipient witnesses. The witnesses will use their specialized medical knowledge to reach opinions about complex medical tests. Notably, the government plans to elicit testimony and opinions from these witnesses about specific Theranos tests for which the government's own retained expert was unable to draw conclusions as to accuracy and reliability. The government intends to use their opinions to do what it cannot do with its retained expert's testimony: to urge the jury to conclude that specific Theranos tests were inaccurate and unreliable. As a matter of due process, Ms. Holmes is entitled to adequate disclosure to challenge those core expert assertions, and to ensure that she can vindicate her constitutional rights when confronting these witnesses.

In any event, the Ninth Circuit has rejected the very argument the government presents here. There is no "percipient witness" or "minimal expert testimony" exception to Rule 16. For each witness who provides expert testimony, the government must provide a summary of that witness's opinion and the bases and reasons for the opinion. As the Ninth Circuit has held, "[t]he mere percipience of a witness to the facts on which he wishes to tender an opinion does not trump Rule 702." *United States v. Figueroa-Lopez*, 125 F.3d 1241, 1246 (9th Cir. 1997).

The government's opposition leaves many of Ms. Holmes' substantive points unanswered. Ms. Holmes does not know the content of some of the experts' opinions; she does not know the bases and reasons for several of the experts' opinions; and she does not have the basic information required to test

MS. HOLMES' REPLY IN SUPPORT OF MOTION TO EXCLUDE EXPERT TESTIMONY OR, IN THE ALTERNATIVE, COMPEL ADEQUATE RULE 16 DISCLOSURE CR-18-00258 EJD

the reliability or credibility of these experts through "focused cross-examination" or to frame a Daubert motion. Id.; see also United States v. Cerna, 2010 WL 2347406, at \*1 (N.D. Cal. June 8, 2010) (the summary of the "bases and reasons must be sufficient to allow counsel to frame a *Daubert* motion"). And the minimal discovery produced by the government does not provide this missing information. The Court should exclude these witnesses from providing expert testimony, or, in the alternative, compel adequate disclosures.

#### ARGUMENT

Federal Rule of Criminal Procedure 16 requires the government to provide, for any witness who may offer expert testimony, a description of the witness's opinions and the bases and reasons for the opinions. The Rule "is intended to minimize surprise that often results from unexpected testimony, reduce the need for continuances, and to provide the opponent with a fair opportunity to test the merit of the expert's testimony through focused cross-examination." Figueroa-Lopez, 125 F.3d at 1246 (quoting Fed. R. Crim. P. 16 Advisory Committee Note). The government fails to provide this basic information for many of its witnesses.

#### The Rule 16 Standards Apply to These Witnesses. I.

The government primarily urges this Court to apply a lower standard than articulated under Rule 16. Gov't Opp'n at 8-10. It argues that for "expert witnesses[] who will be presenting only 'generic' expert testimony, and who will primarily be testifying as percipient witnesses," "all that Rule 16 requires" is limited expert notice. *Id.* at 10. The Court should reject the government's invitation to create such a standard here.

#### Rule 16 Applies to All Expert Testimony.

Rule 16 does not distinguish between percipient and retained expert witnesses. The government cannot skirt Rule 16 by calling these experts percipient witnesses who will provide limited expert testimony. *Id.* at 8-10. Such a tactic is foreclosed by both the Federal Rules and Ninth Circuit precedent. The Advisory Committee Note to Federal Rule of Evidence 701 "makes clear that any part of a witness' testimony that is based upon scientific, technical, or other specialized knowledge . . . is

27

28

1

2

3

5

6

7

8

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

MS. HOLMES' REPLY IN SUPPORT OF MOTION TO EXCLUDE EXPERT TESTIMONY OR, IN THE ALTERNATIVE, COMPEL ADEQUATE RULE 16 DISCLOSURE

governed by the standards of Rule 702 and the corresponding disclosure requirements of the Civil and Criminal Rules." Fed. R. Evid. 701 Advisory Committee Note to 2000 Amendment (emphasis added). The Note explicitly states that "[b]y channeling testimony that is actually expert testimony to Rule 702, the amendment also ensures that a party will not *evade the expert witness disclosure requirements* set forth in Fed. R. Civ. P. 26 and Fed. R. Crim. P. 16 by *simply calling an expert witness in the guise of a layperson.*" *Id.* (emphasis added). Any witness who offers testimony based on scientific, technical, or specialized knowledge is subject to Rule 702, and Rule 16's disclosure requirement is tied to Rule 702. Rule 16 applies to any witness who will offer testimony subject to Rule 702.

The Ninth Circuit has reaffirmed this point. In *Figueroa-Lopez*, the court rejected the very argument that the government makes here—*i.e.*, that lay witnesses' opinions are based on their percipient knowledge and therefore are not subject to the same requirements as expert witnesses. 125 F.3d at 1246. The government argued that the testimony of its witnesses, DEA agents, about the defendant's actions was the proper subject of lay opinion testimony because the testimony was based on the agents' direct observations of the defendant. *Id.* at 1243. As a result, the government argued, the witnesses were "percipient witnesses" not subject to the requirements of Rule 702. *Id.* 

The Ninth Circuit rejected this position, observing that the "Government's argument simply blurs the distinction between Federal Rules of Evidence 701 and 702." *Id.* Rule 701 limits opinions to those "rationally based on the perception of the witness," and Rule 702, "on the other hand, governs admission of expert opinion testimony concerning 'specialized knowledge." *Id.* (emphasis in original). Critically, the court explained that "the Government's argument subverts the requirements of Federal Rule of Criminal Procedure 16(a)(1)(E)... [which] requires the Government to 'disclose to the defendant a written summary of [expert] testimony the government intends to use... during its case in chief." *Id.* That is exactly the circumstance that confronts Ms. Holmes here. The government is attempting to use the label "percipient witness" to avoid its disclosure obligations under Rule 16.

As the court explained, regardless of whether the testimony is based on the witness's perception, if the testimony requires the witness to draw on specialized knowledge, it falls under Rule 702. *Id.; see* 

also Fresenius Med. Care Holdings, Inc. v. Baxter Int'l, Inc., 2006 WL 1330002, at \*3 (N.D. Cal. May 15, 2006) ("Lay opinion testimony is 'not to provide specialized explanations or interpretations that an untrained layman could not make if perceiving the same acts or events." (citation omitted)). Accordingly, the court held that "[t]he mere percipience of a witness to the facts on which he wishes to tender an opinion does not trump Rule 702." Figueroa-Lopez, 125 F.3d at 1246. "A holding to the contrary would encourage the Government to offer all kinds of specialized opinions without pausing first properly to establish the required qualifications of their witnesses." Id.

Goodman v. Staples the Office Superstore, LLC, 644 F.3d 817 (9th Cir. 2011), which the government cites for the proposition that "[t]reating physicians 'are not specially hired to provide expert testimony" and therefore no expert report is required, Gov't Opp'n at 8, is not to the contrary. As an initial matter, *Goodman* construed the civil expert disclosure requirement of Rule 26 of the Federal Rules of Civil Procedure. 644 F.3d at 819. The government provides no authority for the proposition that criminal cases—which concern heightened constitutional protections for the defendant—should borrow standards from the rules of civil procedure when it comes to expert witnesses. But, even if the civil standards were relevant, Goodman does not help the government. Goodman does not hold that "treating physicians are exempted from expert notice" provisions in all cases. Gov't Opp'n at 8. Just the opposite: Goodman explicitly states that when treating physicians testifies on matters outside the treatment of their patients they must provide a report. 644 F.3d at 819-20 ("We hold today that when a treating physician morphs into a witness hired to render expert opinions that go beyond the usual scope of a treating doctor's testimony, the proponent of the testimony must comply with Rule 26(a)(2)."). When a treating physician's testimony extends beyond what he "actually observed and what treatment he provided," a disclosure is required. Walker v. Contra Costa Cty., 2006 WL 3371438, at \*9 (N.D. Cal. Nov. 21, 2006). For the reasons set forth below, the government's experts' testimony goes far beyond what they observed and what treatment they provided.

Relatedly, the government argues that its experts' observations about other laboratories are not opinions at all but merely their own personal observations and therefore fall under Rule 701. Gov't

27

28

20

21

22

23

24

25

Opp'n at 8-9. However, the government cannot disguise these expert opinions as lay testimony simply because an expert witness is also a percipient witness. These "observations" are unquestionably based on specialized knowledge. If the government intends to elicit testimony about the quality, types, and frequency of the errors in different laboratories, specialized knowledge is needed for that opinion to be admissible. Ms. Embry, for example, opined in her FBI interview that in "approximately 20 years" any errors she had with Sonora Quest and Lab Corp "were administrative errors, not clinical ones." Gov't Opp'n, Ex. 6 at 1. That is a specialized opinion: how did she deduce that Sonora Quest's errors were merely "administrative" errors whereas Theranos' alleged errors were "clinical" ones? What is the basis for that distinction? Because of the government's inadequate disclosure, Ms. Holmes can only guess at the answer to that question. As in Figueroa-Lopez, the government's argument "simply blurs the distinction between Federal Rules of Evidence 701 and 702." 125 F.3d at 1246; see also id. (stating that "judges who have heard [specialized] testimony many times . . . must not forget that [their] familiarity with it does not bring it within Rule 701, especially given the purpose of Rule 16"). The government elected to disclose these observations as part of its expert disclosure. Ms. Holmes is entitled to know the bases and reasons for these opinions so she can fairly challenge them at trial.

#### В. The Government Must Provide More Than "Generic" Descriptions.

The government similarly characterizes its experts' testimony as "generic" and, on that basis, argues that Rule 16 requires only a "generic description of the likely witness and that witness's qualifications." Gov't Opp'n at 9 (citing Fed. R. Crim. P. 16, Advisory Committee Notes to 1993 Amendment). According to the government, "[n]othing in these witnesses' expected testimony will present novel or controversial opinions that might be the subject of a *Daubert* hearing," and therefore a generic description suffices. *Id.* That is wishful thinking: these witnesses are presenting substantive opinions on complex medical questions, and their opinions present serious *Daubert* questions. At the very minimum, the government needs to provide basic information such as whether the witnesses' opinions are based on known objective facts concerning specific patients and why those facts led them to believe that the Theranos tests were inaccurate.

27

28

1

2

3

4

5

6

7

8

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

MS. HOLMES' REPLY IN SUPPORT OF MOTION TO EXCLUDE EXPERT TESTIMONY OR, IN THE ALTERNATIVE, COMPEL ADEQUATE RULE 16 DISCLOSURE CR-18-00258 EJD

There is nothing "generic" or routine about the testimony of these witnesses. The following examples illustrate how the government intends to elicit opinion testimony that goes well beyond the treatment of a specific patient and is not simply "generic":

- The government plans to elicit testimony from Dr. Linnerson about "problematic hCG test results from Theranos," although it has only identified one patient who received a "problematic" result. *See* Gov't Opp'n at 2. It also plans to elicit testimony about "the actions he and his clinic took" in setting up "a small study" comparing his clinic's patients hCG results with other laboratories and that the results of the study "failed to restore confidence" in Theranos' tests. *Id.* at 2-3. If anything is subject to Rule 702 and *Daubert*, testimony about a medical "study" and the interpretation of the study results surely is.
- The government also plans to elicit testimony from Dr. Zachman about this same study and how she "worked with Dr. Linnerman [sic] and others in the clinic" to conduct the study. *Id*. at 3.
- Dr. Szmuc worked in the same practice as Drs. Linnerson and Zachman, and the government will attempt to elicit opinions concerning the hypothetical ramifications of inaccurate tests such as ordering "surgical or pharmaceutical intervention." *Id.* at 4.
- The government plans to elicit from Ms. Embry that Theranos tests could have hypothetically caused patient harm if she adjusted a patient's medication based on a Theranos test. Gov't Opp'n, Ex. 6 at 3. It also intends to ask her to opine that any unexpected Theranos results were clinical errors, but that unexpected Sonora Quest results were "administrative errors." *Id.* at 1. No basis for that opinion has been described.
- Dr. Page will testify that "he did not understand how Theranos could not have known they
  had a problem with A1Cs for months." Gov't Opp'n at 8. This opinion, if offered,
  necessarily draws on his specialized knowledge. This testimony does not merely describe his
  percipient observations; it opines on what Theranos should have known based on those

- observations. And this opinion presents significant questions under *Daubert*, because it is unclear that Dr. Page has a sufficient basis to offer such an opinion.
- The government disclosed that Dr. Asin will opine that a Theranos test result for an HIV test that was reactive for certain antibodies and not reactive for others "did not make sense." *Id.* at 6-7. This is an expert opinion that draws on his specialized knowledge. And depending on the principles he applied to reach this opinion, it could well be subject to challenge under *Daubert*. The government also disclosed that Dr. Asin will opine on a hypothetical invasive procedure that a doctor may order to recheck a PSA test, though he identifies no patient for whom such a procedure was performed. *Id.* at 7.

Contrary to the government's argument, these disclosures indicate that the government intends to elicit medical expert testimony that goes well beyond "merely . . . explaining what the values for [Theranos] tests mean." *Id.* at 9.

The government's assertion that the witnesses' expected testimony will not present controversial opinions that might be the subject for a *Daubert* hearing reflects a fundamental misunderstanding of the standards articulated in *Daubert*. What are the bases for the witnesses' opinions? Have they relied on sufficiently reliable data in forming their opinions? What is that data? To the extent their opinions about the accuracy of Theranos tests rest on isolated patient anecdotes and not a reliable body of data or evidence, their opinions will present serious reliability problems. *See, e.g., Vollrath Co. v. Sammi Corp.*, 9 F.3d 1455, 1462 (9th Cir. 1993). Ms. Holmes cannot even begin to provide answers for those questions because of the government's failure to provide a sufficiently detailed disclosure. *See Cerna*, 2010 WL 2347406, at \*1 (stating that the summary of the "bases and reasons must be sufficient to allow counsel to frame a *Daubert* motion").

The experts' opinions, moreover, go to a core issue in this case: the accuracy and reliability of Theranos tests. Critically, the government's retained expert, Dr. Stephen Master, has offered only limited opinions about Theranos tests. In his expert report, Dr. Master fails to offer an actual opinion about whether Theranos' hCG, HIV, A1C or calcium test were accurate and reliable; his report indicates

MS. HOLMES' REPLY IN SUPPORT OF MOTION TO EXCLUDE EXPERT TESTIMONY OR, IN THE ALTERNATIVE, COMPEL ADEQUATE RULE 16 DISCLOSURE CR-18-00258 EJD

that he lacks sufficient data to reach an opinion on those subjects. See Declaration of Amy Mason Saharia ("Saharia Decl."), Ex. A. at 12 (Expert Disclosure of Dr. Stephen Master) (explaining only that he had "questions" about these tests). The government apparently intends to use these witnesses to fill the holes in those opinions. In fact, the disclosed experts cover all the tests for which Dr. Master was unable to opine: hCG (Linnerson, Zachman, Szmuc), A1C (Page), HIV (Asin), and calcium (Asin). See Gov't Opp'n at 2-8. Their testimony is quintessential expert opinion testimony, and it goes to a core issue in this case. The government must be required to comply with Rule 16.

Finally, the government ignores that, even if it were permitted to provide a "generic" description of its witnesses' opinions, it must also provide the bases and reasons for those opinions. Rule 16 provides three distinct requirements for an expert summary: (1) "the witness's opinions;" (2) "the bases and reasons for those opinions;" and (3) "the witness's qualifications." Fed. R. Crim. P. 16(a)(1)(G). The Advisory Committee Notes to the 1993 Amendment—on which the government relies—allow for a "generic description" in some instances of the "summary of the expected testimony." However, for the "most important" requirement—the "summary of the bases of the expert's opinion"—the Notes do not allow the government to provide a generic description:

> Without regard to whether a party would be entitled to the underlying bases for expert testimony under other provisions of Rule 16, the amendment requires a summary of the bases relied upon by the expert. That should cover not only written and oral reports, tests, reports, and investigations, but any information that might be recognized as a legitimate basis for an opinion under Federal Rule of Evidence 703.

Fed. R. Crim. P. 16 Advisory Committee Notes to 1993 Amendment.

*United States v. Cerna*, the case on which the government relies for its "generic" argument, proves the point. It states that "where a witness is so 'generic' and routine (such as a DEA laboratory chemist) that the testimony will be largely predictable, a shorthand summary of the witness's qualifications and testimony may be adequate." 2010 WL 2347406, at \*1 (emphasis added). However, the "summary of bases relied upon by the expert 'should cover . . . any information that might be recognized as a legitimate basis for an opinion under Federal Rule of Evidence 703." Id. (citing Fed. R.

27

28

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

MS. HOLMES' REPLY IN SUPPORT OF MOTION TO EXCLUDE EXPERT TESTIMONY OR, IN THE ALTERNATIVE, COMPEL ADEQUATE RULE 16 DISCLOSURE CR-18-00258 EJD

CR-18-00258 EJD

Crim. P. 16 Advisory Committee Notes to 1993 Amendment). The government cannot escape this requirement by labeling its expert witnesses' testimony as "generic."

### **II.** The Government's Disclosure Remains Inadequate.

# A. The Government Failed To Provide a Summary for Its Experts' Opinions and the Bases and Reasons for Those Opinions.

For the reasons set forth in Ms. Holmes' motion, the government's disclosure is, and remains, inadequate. *See* Def.'s Mot. To Exclude Expert Testimony ("Def.'s Mot."), ECF No. 435. *First*, for two witnesses, Dr. Page and Dr. Asin, it does not provide an opinion at all—it just states that the witnesses will testify about certain tests. *Id.* at 3-4. *Second*, the government failed to provide the bases and reasons for many of the opinions that it does identify. *Id.* at 3-7. And, for the reasons set forth above, these opinions go far beyond percipient testimony of a treating physician.

Rule 16 demands more. The government has not provided and is required to provide the following:

- 1. An explicit opinion for each Theranos test referenced in each witness's summary;
- 2. The specific patients and test results on which the witnesses are basing their opinions (or it should clarify that there are no specific patients);
- The bases of and reasons for their conclusions that such test results were inaccurate or unreliable; and
- 4. The bases of and reasons for their opinions regarding the accuracy of other laboratories' tests.

This should not be a difficult task. If the government is going to proffer these witnesses to offer opinions about a central allegation—that Theranos tests were inaccurate and unreliable—as its opposition and disclosure indicate it will, the Constitution and Rule 16 entitle Ms. Holmes to this bare minimum of information.

### B. The Government's Discovery Does Not Cure Its Insufficient Disclosure.

The government tries to paper over the obvious gaps in its disclosure by pointing generally to discovery in this case. *See* Gov't Opp'n at 9. Although discovery may provide context for the summary of the witnesses' testimony, "the production of additional documents cannot satisfy a rule that requires a MS. HOLMES' REPLY IN SUPPORT OF MOTION TO EXCLUDE EXPERT TESTIMONY OR, IN THE ALTERNATIVE, COMPEL ADEQUATE RULE 16 DISCLOSURE

- "summary" that "describe[s] . . . the *bases and reasons* for [the expert witness's] opinions." *United States v. Valdez*, 2019 WL 539074, at \*3 (N.D. Cal. Feb. 11, 2019) (emphasis added). The government has not shown, and cannot show, that the discovery discloses the bases and reasons for the doctors' opinions, for several reasons:
- 1. The government's one-paragraph defense of its disclosures says nothing about providing the bases and reasons for its witnesses' opinions. The government refuses to confront this requirement and for that reason alone its arguments must fail.
- 2. The government seizes on its assertion that it has "provided all the relevant discovery in its custody and control relating to doctor witnesses, as well as their patients." Gov't Opp'n at 9. But this discovery is extremely limited. Across the seven experts, the collective interview memoranda name *four* total patients. A number of these experts did not name a single patient who formed the basis for their opinions. The government has produced a grand total of *two* interview memoranda for patients of these experts. And, in many cases, the government collected *no* or extremely limited documents from these experts. This limited amount of disclosure does not help Ms. Holmes figure out the basis and reasons for these experts' opinions.
- 3. With respect to the two experts for which the government did not even disclose an opinion for certain tests (Dr. Page and Dr. Asin), the government points to its discovery production, including its FBI 302 interview memoranda. But Dr. Page's and Dr. Asin's disclosures do not fix this problem. Dr. Page's 302 says nothing about what his opinion will be for complete blood count (CBC) tests. *Id.* at 7-8. For Dr. Asin, the government states that Dr. Asin "recalled" that Theranos diabetic tests did not "seem as accurate, and protein and calcium tests that seemed incorrect as well," but that barebones assertion come nowhere close to complying with Rule 16. *Id.* at 7. It says nothing about why or how he reached that opinion.
- 4. The government complains that it does not have the ability to search for patients in Theranos' database. *Id.* at 7 n.1.<sup>1</sup> But the government's inability to substantiate its experts' "opinions"

<sup>&</sup>lt;sup>1</sup> It bases this assertion on a statement made in a civil case about a civil litigant's attempt to access the database. The government, which has highly sophisticated data recovery abilities, says nothing about its MS. HOLMES' REPLY IN SUPPORT OF MOTION TO EXCLUDE EXPERT TESTIMONY

OR, IN THE ALTERNATIVE, COMPEL ADEQUATE RULE 16 DISCLOSURE CR-18-00258 EJD

with data does not allow it to circumvent Rule 16 (or the *Daubert* standards for that matter). The government argues that it has to "piece together" test results from records patients may have kept or from records within doctors' offices. *Id.* But, as just set forth, it has not consistently done so. If it had done so, it presumably would have identified actual patients in its disclosures. Equally importantly, if that is so, the same holds true for Ms. Holmes. Ms. Holmes cannot "piece together" the bases for these experts' opinions without a complete and accurate disclosure, and the government should not be permitted to substitute vague opinions for the investigative work it needs to do to prove its case. Ms. Holmes needs to know which records and patients form the bases for these experts' opinions, to avoid unfair surprise at trial and to enable her to serve Rule 17 subpoenas to access relevant evidence.

The government's opposition and discovery resolve none of these problems. The Court should exclude the testimony of the government's experts. In the alternative, the Court should order the government to provide an adequate disclosure.

#### CONCLUSION

For these reasons, this Court should grant Ms. Holmes' motion.

16 DATED

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

18

19

DATED: July 13, 2020 Respectfully submitted,

17 |

/s/ Amy Mason Saharia

KEVIN DOWNEY LANCE WADE

AMY MASON SAHARIA KATHERINE TREFZ

Attorneys for Elizabeth Holmes

2021

22

23

24

25

26

28

27 own attempts, if any, to access the patient database.

MS. HOLMES' REPLY IN SUPPORT OF MOTION TO EXCLUDE EXPERT TESTIMONY

OR, IN THE ALTERNATIVE, COMPEL ADEQUATE RULE 16 DISCLOSURE

CR-18-00258 EJD

**CERTIFICATE OF SERVICE** I hereby certify that on July 13, 2020 a copy of this filing was delivered via ECF on all counsel of record. /s/ Amy Mason Saharia AMY MASON SAHARIA Attorney for Elizabeth Holmes MS. HOLMES' REPLY IN SUPPORT OF MOTION TO EXCLUDE EXPERT TESTIMONY OR, IN THE ALTERNATIVE, COMPEL ADEQUATE RULE 16 DISCLOSURE

CR-18-00258 EJD